Scientists at the Mayo Clinic have finally solved the molecular structure of protein kinase C beta (PKCβ), a protein implicated in cancer and neurological diseases. The breakthrough, published in Nature Communications, ends a nearly four-decade-long search to understand how the protein operates at the atomic level.
The discovery provides the first detailed view of PKCβ's mechanism, revealing how it interacts with cellular signals that can drive disease. This clarity allows researchers to see exactly how the breast cancer drug endoxifen binds to and targets the protein, offering a blueprint for developing more precise therapies.
According to the study, the structure shows specific conformational changes that occur when PKCβ is activated. These details explain why certain mutations in the protein lead to uncontrolled cell growth, a hallmark of cancer, and how endoxifen can inhibit this process.
The findings could accelerate the design of new drugs not only for breast cancer but also for conditions like Alzheimer's disease and other neurological disorders where PKCβ plays a role. Mayo Clinic researchers aim to leverage this structural data to identify additional compounds that might target the protein more effectively.
Independent experts caution that while the structural data is promising, translating it into viable treatments will require years of clinical testing. The path from molecular discovery to approved therapy remains long and uncertain.